Terms: = Leukemia AND PR, PGR, progesterone receptor AND Prognosis
137 results:
1. [The Efficacy and Safety of Venetoclax Combined with Azacitidine in the Treatment of Adult Patients with Acute Myeloid leukemia Who Are Unfit for Intensive Chemotherapy].
Wang KY; Fan BR; Zhang QW; Han MR; Ge XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):342-346. PubMed ID: 38660834
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China.
Luo L; Jiao Y; Li Y; Yang P; Gao J; Huang S; Huang W; Wang J; Dong F; Ke X; Zou D; Gao C; Jing H
Ann Hematol; 2024 Jun; 103(6):2073-2087. PubMed ID: 38581546
[TBL] [Abstract] [Full Text] [Related]
3. Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders.
Liu DL; Wang YJ; Qian SY; Ma SS; Ding MJ; Dong M; Zhang JM; Zhang MZ; Chen QJ; Zhang XD
Hematology; 2024 Dec; 29(1):2307817. PubMed ID: 38319083
[TBL] [Abstract] [Full Text] [Related]
4. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
Stilgenbauer S; Tausch E; Roberts AW; Davids MS; Eichhorst B; Hallek M; Hillmen P; Schneider C; Schetelig J; Böttcher S; Kater AP; Jiang Y; Boyer M; Popovic R; Ghanim MT; Moran M; Sinai WJ; Wang X; Mukherjee N; Chyla B; Wierda WG; Seymour JF
Blood Adv; 2024 Apr; 8(8):1992-2004. PubMed ID: 38290108
[TBL] [Abstract] [Full Text] [Related]
5. [Safety and the Short-Term Efficacy of Venetoclax Combined with Azacitidine Followed by Cladribine in Children with Refractory/Relapsed Acute Myeloid leukemia].
DU WW; Liu SX; Wang Y; He HL; Guo AL; Hu SY; Lu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1635-1638. PubMed ID: 38071039
[TBL] [Abstract] [Full Text] [Related]
6. [Chemotherapy Combined with Venetoclax Followed by Allo-Hematopoietic Stem Cell Transplantation for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang LL; Wang QX; Guan J; Zhou Y; Hu B; Feng Y; Zou L; Cheng H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1531-1536. PubMed ID: 37846712
[TBL] [Abstract] [Full Text] [Related]
7. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for T lymphoblastic leukemia/lymphoma].
Luo L; Jiao Y; Yang P; Li Y; Huang WY; Ke XY; Zou DH; Jing HM
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):388-394. PubMed ID: 37550188
[No Abstract] [Full Text] [Related]
8. [Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang QX; Wang LL; Guan J; Zhou Y; Zhang T; Su F; Chen LQ; Cao Y; Cheng H; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):896-901. PubMed ID: 37356957
[TBL] [Abstract] [Full Text] [Related]
9. Myelodysplastic Syndrome Treated by Integrated Chinese and Western Medicine: A Case Report.
Jie W; Xiaoqing D; Haiyan C; Ming G; Junxia L; Ling L; Jun L; Jing L
Altern Ther Health Med; 2023 Sep; 29(6):248-253. PubMed ID: 37295013
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia.
Yao H; Zhang C; Tan X; Li J; Yin X; Deng X; Chen T; Rao J; Gao L; Kong P; Zhang X
Cancer Med; 2023 Jun; 12(11):12377-12387. PubMed ID: 37161845
[TBL] [Abstract] [Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis.
Berning P; Schmitz N; Ngoya M; Finel H; Boumendil A; Wang F; Huang XJ; Hermine O; Philippe L; Couronné L; Jaccard A; Liu D; Wu D; Reinhardt HC; Chalandon Y; Wagner-Drouet E; Kwon M; Zhang X; Carpenter B; Yakoub-Agha I; Wulf G; López-Jiménez J; Sanz J; Labussière-Wallet H; Shimoni A; Dreger P; Sureda A; Kim WS; Glass B
Leukemia; 2023 Jul; 37(7):1511-1520. PubMed ID: 37157017
[TBL] [Abstract] [Full Text] [Related]
12. Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
Jin H; Zhang Y; Yu S; Du X; Xu N; Shao R; Lin D; Chen Y; Xiao J; Sun Z; Deng L; Liang X; Zhang H; Guo Z; Dai M; Shi P; Huang F; Fan Z; Yin Z; Xuan L; Lin R; Jiang X; Yu G; Liu Q
J Hematol Oncol; 2023 Apr; 16(1):42. PubMed ID: 37120593
[TBL] [Abstract] [Full Text] [Related]
13. [Efficacy and Safety of Decitabine Combined with Modified EIAG Regimen in the Treatment of Patients with Relapsed/Refractory Acute Myeloid leukemia and High-risk Myelodysplastic Syndrome].
Mao JP; Xue LG; Zhu YX; Jia T; Wang Y; Miao L; Wei JF; Zhao LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):338-343. PubMed ID: 37096503
[TBL] [Abstract] [Full Text] [Related]
14. [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].
Chen X; Liu ZY; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):542-549. PubMed ID: 36709130
[No Abstract] [Full Text] [Related]
15. Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
Tanaka T; Inamoto Y; Ito A; Watanabe M; Takeda W; Aoki J; Kim SW; Fukuda T
Hematol Oncol; 2023 Aug; 41(3):389-395. PubMed ID: 36513602
[TBL] [Abstract] [Full Text] [Related]
16. Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion.
Tang Y; Yang D; Xie R; Zhong Z; You Y
Transpl Immunol; 2023 Feb; 76():101743. PubMed ID: 36372140
[TBL] [Abstract] [Full Text] [Related]
17. The Deubiquitinating Enzyme USP4 Functions as an Oncoprotein in Gastric Cancer and Mediates NF-κB Signaling by Regulating PRL-3 Expression.
Tao Y; You W
Front Biosci (Landmark Ed); 2022 Oct; 27(10):286. PubMed ID: 36336860
[TBL] [Abstract] [Full Text] [Related]
18. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.
Pagano L; Criscuolo M; Broccoli A; Piciocchi A; Varettoni M; Galli E; Anastasia A; Cantonetti M; Trentin L; Kovalchuk S; Orsucci L; Frustaci A; Spolzino A; Volpetti S; Annibali O; Storti S; Stelitano C; Marchesi F; Offidani M; Casadei B; Nizzoli ME; De Luca ML; Fianchi L; Motta M; Guarnera L; Simonetti E; Visentin A; Vassallo F; Deodato M; Sarlo C; Olivieri A; Falini B; Pulsoni A; Tiacci E; Zinzani PL
Blood Cancer J; 2022 Jul; 12(7):109. PubMed ID: 35853850
[TBL] [Abstract] [Full Text] [Related]
19. [Effects of interferon regulatory factor 9 on the biological phenotypes in PML-RARα-induced promyelocytic leukemia].
Yang X; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):370-375. PubMed ID: 35680593
[No Abstract] [Full Text] [Related]
20. Changes in Ki-67 in Residual Tumor and Outcome of Primary Inflammatory Breast Cancer Treated With Trimodality Therapy.
Song Z; Li C; Zhou D; Liu J; Qian X; Zhang J
Clin Breast Cancer; 2022 Jul; 22(5):e655-e663. PubMed ID: 35248490
[TBL] [Abstract] [Full Text] [Related]
[Next]
